| ID: | 86 | |
|---|---|---|
| Name: | Compound 86 | |
| Description: | Original numeration in publication: 31a | |
| Labels: | Training_set, Quinoxalines | |
| CAS: | ||
| InChi Code: | InChI=1S/C25H21N5O3S/c1-16-25(28-21-10-6-5-9-20(21)26-16)34-15-22(31)27-19-13-11-18(12-14-19)24(33)30-29-23(32)17-7-3-2-4-8-17/h2-14H,15H2,1H3,(H,27,31)(H,29,32)(H,30,33) |
pIC50: Negative logarithm of half-maximal inhibitory concentration [-log(uM)]
| Value | Source or prediction |
|---|---|
| 7.97 |
Alanazi, M. M.; Eissa, I. H.; Alsaif, N. A. a. O., A. J.; Alanazi, W. A.; Alasmari, A. F. a. A., H.; Elkady, H.; Elwan, A. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers. J. Enzyme Inhib. Med. Chem. 2021, 36, 1760–1782. https://doi.org/10.1080/14756366.2021.1956488 |
| 7.65402 |
Eq1: VEGFR-2 inhibition (Data used to train model) |